Immune-related adverse events as predictors of pathological complete response in early-stage triple-negative breast cancer treated with pembrolizumab.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Güren Ali Kaan, Demircan Nazım Can, Gümüşay Özge, Şimşek Eda Tanrıkulu, Kemik Fatih, Karaoğlu Çağla, Şahin Taha Koray, Tünbekici Salih, Akkaya Kübra, Guliyev Murad, Gezici Barış, Gür Hasibe Bilge, Karakaş Delyadil, Ünlü Ahmet, Altunok Oğuz, Nazlı İsmail, Biter Sedat, Kaya Tuğba, Yetginoğlu Özge, Güneş Tuğçe Kübra, Şeker Can Lamia, Majidova Nargiz, Sever Nadiye, Akkuş Aysun Fatma, Kara İsmail Oğuz, Öztürk Banu, Deligönül Adem, Kaplan Muhammet Ali, Atağ Elif, Hacıbekiroğlu İlhan, Demirci Nebi Serkan, Biricik Fatih Selçuk, Güven Deniz Can, Aksoy Sercan, Arıkan Rukiye, Sarı Murat, Bayoğlu İbrahim Vedat, Köstek Osman
Аннотация
METHOD: In this multicenter retrospective study, early TNBC patients who received neoadjuvant pembrolizumab-based therapy were evaluated. Clinicopathologic features, irAE occurrence, and pCR rates were recorded and analyzed.
RESULTS: Among 203 patients who completed neoadjuvant treatment and underwent surgery, 127 (62.6%) achieved pCR. irAEs were more frequent in the pCR group compared with the non-pCR group (35.4% vs 19.7%, respectively; p = 0.01). Both univariate and multivariate analyses confirmed a significant association between irAE development and pCR.
CONCLUSION: In patients with early TNBC treated with neoadjuvant pembrolizumab, irAEs occurred more often in those achieving pCR. These findings suggest that irAEs may reflect enhanced immune activation and could serve as a potential indicator of treatment response. Further prospective studies are needed to validate this observation and clarify its clinical relevance.